A post-approval ( PA ) study for destination therapy ( DT ) was required by the Food and Drug Administration ( FDA ) to determine whether results with the HeartMate ( HM ) II ( Thoratec , Pleasanton , California ) left ventricular assist device ( LVAD ) in a commercial setting were comparable to results during the DT multicenter pivotal clinical trial .